299 related articles for article (PubMed ID: 31409052)
1. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
Kim S; Kim N; Kang K; Kim W; Won J; Cho J
Cells; 2019 Aug; 8(8):. PubMed ID: 31409052
[TBL] [Abstract][Full Text] [Related]
2. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
3. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
4. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
7. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
8. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
9. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX
Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236
[TBL] [Abstract][Full Text] [Related]
10. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
Ye H; Liu Y; Wu K; Luo H; Cui L
Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
[TBL] [Abstract][Full Text] [Related]
11. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
12. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
[TBL] [Abstract][Full Text] [Related]
13. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
[TBL] [Abstract][Full Text] [Related]
14. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
Arriga R; Caratelli S; Lanzilli G; Ottaviani A; Cenciarelli C; Sconocchia T; Spagnoli GC; Iezzi G; Roselli M; Lauro D; Coppola A; Dotti G; Ferrone S; Sconocchia G
Int J Cancer; 2020 May; 146(9):2531-2538. PubMed ID: 31396956
[TBL] [Abstract][Full Text] [Related]
15. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
Zhang H; Yuan L; Liu L; Yan C; Cheng J; Fu Q; Tong Z; Jiang W; Zheng Y; Zhao P; Zhang G; Fang W
BMC Cancer; 2020 May; 20(1):416. PubMed ID: 32404198
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
Nakadate Y; Kodera Y; Kitamura Y; Shirasawa S; Tachibana T; Tamura T; Koizumi F
Int J Cancer; 2014 May; 134(9):2146-55. PubMed ID: 24136682
[TBL] [Abstract][Full Text] [Related]
17. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer.
Yang L; Bhattacharya A; Li Y; Sexton S; Ling X; Li F; Zhang Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):184. PubMed ID: 35650607
[TBL] [Abstract][Full Text] [Related]
18. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
[TBL] [Abstract][Full Text] [Related]
19. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
